Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
Name
18361
Description
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
Trial arms
Trial start
2022-07-20
Estimated PCD
2024-03-04
Trial end
2024-06-03
Status
Active (not recruiting)
Phase
Early phase I
Treatment
LY3561774
Administered SC
Arms:
LY3561774 Dose 1, LY3561774 Dose 2, LY3561774 Dose 3
Placebo
Administered SC
Arms:
Placebo
Size
175
Primary endpoint
Percent Change from Baseline for Apolipoprotein B (ApoB)
Baseline, Day 180
Eligibility criteria
Inclusion Criteria:
* Have fasting triglycerides (TGs) within the range of 150 (1.69 millimole/liter (mmoL) to 499 milligram/deciliter (mg/dL) 2.26 to 5.64 millimole/liter (mmol/L) at screening.
* Have fasting LDL-C ≥70 mg/dL (1.81 mmol/L) at screening.
* Have non-HDL-C ≥ 130 mg/dL (3.36 mmol/L) at screening.
* Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study.
* Have a body mass index within the range of 18.5 to 40.0 kilogram/square meter (kg/m²), inclusive
Exclusion Criteria:
* Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an hemoglobin A1c (HbA1c) ≥8% at screening.
* Have a history of nephrotic syndrome.
* Have a history of acute or chronic pancreatitis.
* Have had within the past 3 months prior to screening
* Myocardial infarction
* Unstable angina
* Coronary artery bypass graft
* Percutaneous coronary intervention - diagnostic angiograms are permitted
* Peripheral artery disease
* Transient ischemic attack, or
* Cerebrovascular accident
* Have New York Heart Association Class III or IV heart failure or last known left ventricular ejection fraction \<30%.
* Have undergone LDL apheresis within 12 months prior to screening.
* Have clinically relevant anemia, as defined by the investigator.
* Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.
* Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.
* Have uncontrolled hypertension.
* Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 175, 'type': 'ESTIMATED'}}
Updated at
2024-05-28
1 organization
1 product
1 drug
4 indications
Organization
Eli Lilly and CompanyProduct
LY3561774Indication
DyslipidemiaIndication
Lipid Metabolism DisordersIndication
Metabolic DiseasesIndication
HyperlipoproteinemiaDrug
Varlilumab